Pulmatrix Net Worth
Pulmatrix Net Worth Breakdown | PULM |
Pulmatrix Net Worth Analysis
Pulmatrix's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Pulmatrix's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Pulmatrix's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Pulmatrix's net worth analysis. One common approach is to calculate Pulmatrix's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Pulmatrix's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Pulmatrix's net worth. This approach calculates the present value of Pulmatrix's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Pulmatrix's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Pulmatrix's net worth. This involves comparing Pulmatrix's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Pulmatrix's net worth relative to its peers.
Enterprise Value |
|
To determine if Pulmatrix is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Pulmatrix's net worth research are outlined below:
| Pulmatrix is way too risky over 90 days horizon | |
| Pulmatrix appears to be risky and price may revert if volatility continues | |
| Pulmatrix has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 7.3 M. Net Loss for the year was (14.12 M) with profit before overhead, payroll, taxes, and interest of 6.07 M. | |
| Pulmatrix currently holds about 42.91 M in cash with (15.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Pulmatrix has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Disposition of 25000 shares by Siegert Michelle of Pulmatrix at 1.06 subject to Rule 16b-3 |
Pulmatrix uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Pulmatrix. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Pulmatrix's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Pulmatrix's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Pulmatrix is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pulmatrix backward and forwards among themselves. Pulmatrix's institutional investor refers to the entity that pools money to purchase Pulmatrix's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Wells Fargo & Co | 2024-06-30 | 0.0 | Citigroup Inc | 2024-06-30 | 0.0 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 0.0 | Gradient Investments | 2024-09-30 | 0.0 | Renaissance Technologies Corp | 2024-09-30 | 117.2 K | Blackrock Inc | 2024-06-30 | 54.9 K | Vanguard Group Inc | 2024-09-30 | 35.1 K | Geode Capital Management, Llc | 2024-06-30 | 26.5 K | State Street Corp | 2024-06-30 | 13.9 K | Tower Research Capital Llc | 2024-06-30 | 4.9 K | Ubs Group Ag | 2024-06-30 | 3.8 K |
Follow Pulmatrix's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 22.32 M.Market Cap |
|
Project Pulmatrix's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | (0.49) | (0.52) | |
| Return On Assets | (0.42) | (0.44) | |
| Return On Equity | (0.78) | (0.82) |
When accessing Pulmatrix's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Pulmatrix's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Pulmatrix's profitability and make more informed investment decisions.
Evaluate Pulmatrix's management efficiency
Pulmatrix has return on total asset (ROA) of (0.2999) % which means that it has lost $0.2999 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5899) %, meaning that it created substantial loss on money invested by shareholders. Pulmatrix's management efficiency ratios could be used to measure how well Pulmatrix manages its routine affairs as well as how well it operates its assets and liabilities. As of the 23rd of November 2024, Return On Tangible Assets is likely to drop to -0.44. In addition to that, Return On Capital Employed is likely to drop to -0.52. At this time, Pulmatrix's Non Currrent Assets Other are very stable compared to the past year. As of the 23rd of November 2024, Total Current Assets is likely to grow to about 22.2 M, while Non Current Assets Total are likely to drop about 8.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.93 | 4.68 | |
| Tangible Book Value Per Share | 4.93 | 4.68 | |
| Enterprise Value Over EBITDA | 0.29 | 0.30 | |
| Price Book Value Ratio | 0.38 | 0.40 | |
| Enterprise Value Multiple | 0.29 | 0.30 | |
| Price Fair Value | 0.38 | 0.40 | |
| Enterprise Value | -3.6 M | -3.8 M |
The decision-making processes within Pulmatrix are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Enterprise Value Revenue 1.1528 | Revenue 11.4 M | Quarterly Revenue Growth (0.16) | Revenue Per Share 3.119 | Return On Equity (0.59) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pulmatrix insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pulmatrix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pulmatrix insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Siegert Michelle 3 days ago Disposition of 25000 shares by Siegert Michelle of Pulmatrix at 1.06 subject to Rule 16b-3 | ||
Cabell Christopher few days ago Acquisition by Cabell Christopher of 22100 shares of Pulmatrix at 0.3701 subject to Rule 16b-3 | ||
Gillis Steven over three months ago Acquisition by Gillis Steven of 111 shares of Pulmatrix at 110.0 subject to Rule 16b-3 | ||
Gillis Steven over three months ago Disposition of 880 shares by Gillis Steven of Pulmatrix at 28.0 subject to Rule 16b-3 | ||
Teofilo Raad over a year ago Acquisition by Teofilo Raad of 34900 shares of Pulmatrix subject to Rule 16b-3 |
Pulmatrix Corporate Filings
8K | 13th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 17th of May 2024 Other Reports | ViewVerify |
Pulmatrix Earnings per Share Projection vs Actual
Pulmatrix Corporate Management
| MBA CMA | Interim Officer | Profile | |
| Alexander Klibanov | Founder | Profile | |
| Margaret MD | Chief Officer | Profile | |
| David JD | Advisor | Profile | |
| Aidan Curran | VP Affairs | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulmatrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmatrix. If investors know Pulmatrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmatrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.64) | Revenue Per Share 3.119 | Quarterly Revenue Growth (0.16) | Return On Assets (0.30) | Return On Equity (0.59) |
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmatrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmatrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmatrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.